重组人血管内皮抑素联合GP方案治疗晚期非小细胞肺癌30例疗效观察

目的探讨我国自主开发的新型重组人血管内皮抑素（恩度）联合化疗的疗效及用药安全性。方法 2008年1月-2010年4月海南省人民医院收治的55例晚期非小细胞肺癌（NSCLC）患者,随机分为两组：对照组25例单用GP（吉西他滨＋顺铂）方案治疗;试验组30例采用GP联合恩度方案治疗。化疗至少两个周期以上。结果对照组CR为0,PR为24.0%,SD为52.0%,PD为24.0%;试验组CR为0,PR为53.3%,SD为43.3%,PD为3.33%。试验组和对照组的总RR分别为53.3%和24.0%（P〈0.05）,总CBR分别为96.7%和76.0%（P〈0.05）,试验组和对照组不良反应的发生率差异均无统计学意义（P〉0.05）。结论恩度联合GP方案化疗明显增加晚期NSCLC治疗的有效率及临床受益率,其毒副作用可以耐受。

Efficacy of endostar combined with vinorelbine and cisplatin in treatment of advanced non-small-cell lung cancer

Objective To study the efficacy and safety about our own new recombinant human endostatin combined with chemotherapy.Methods From January 2008 to April 2010,55 patients with lung cancer were treated,and were randomly divided into two groups：25 cases in control group treated with gemcitabine＋cisplatin;30 patients in experimental group treated with endostar combined with gemcitabine＋cisplatin.Results The CR of control group was 0,PR was 24.0%,SD was 52.0%,PD was 24.0%,RR was 24.0%,and CBR was 76.0%.The CR of experimental group was 0,PR was 53.3%,SD was 43.3% and PD was 3.33%.Overall response rate was 53.3% in experimental group and 24.0 % in control group（P〈0.05）.The clinical benefit rate was 96.7% in experimental group and 76.0% in control group（P〈0.05）.There were no significant differences in incidence of adverse events between experimental group and control group.Conclusion The addition of endostar to GP regimen results in significantly and clinically meaningful improvement in response rate and clinical benefit rate compared with GP alone in advanced NSCLC patients,with the tolerated toxicity.